$-0.17 EPS Expected for Endologix, Inc. (ELGX)

October 15, 2017 - By Max Morgan

 $ 0.17 EPS Expected for Endologix, Inc. (ELGX)
Investors sentiment decreased to 0.82 in 2017 Q2. Its down 0.35, from 1.17 in 2017Q1. It dived, as 30 investors sold Endologix, Inc. shares while 31 reduced holdings. 16 funds opened positions while 34 raised stakes. 86.54 million shares or 7.40% less from 93.45 million shares in 2017Q1 were reported.
State Board Of Administration Of Florida Retirement System reported 0% in Endologix, Inc. (NASDAQ:ELGX). Accredited Invsts Incorporated reported 100,000 shares or 0.13% of all its holdings. Rathbone Brothers Public Ltd has invested 0% in Endologix, Inc. (NASDAQ:ELGX). Creative Planning holds 0% or 1,500 shares. Cortina Asset Ltd holds 725,661 shares or 0.15% of its portfolio. California State Teachers Retirement holds 145,685 shares. Credit Suisse Ag holds 0% or 43,838 shares in its portfolio. Goldman Sachs Gp accumulated 493,590 shares or 0% of the stock. Deutsche Bank & Trust Ag stated it has 187,626 shares or 0% of all its holdings. Raymond James Financial Services Inc invested 0% in Endologix, Inc. (NASDAQ:ELGX). Brown Capital Mgmt Ltd Liability holds 0.52% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 8.78 million shares. Wellington Management Grp Inc Ltd Liability Partnership stated it has 0% in Endologix, Inc. (NASDAQ:ELGX). Moreover, Verition Fund Mngmt Limited has 0.01% invested in Endologix, Inc. (NASDAQ:ELGX) for 22,789 shares. Kopp Investment Advsrs Ltd Co has 21,950 shares. Clearbridge Invs Limited Liability invested in 0% or 14,138 shares.

Since May 19, 2017, it had 5 insider purchases, and 0 selling transactions for $329,126 activity. 25,000 shares were bought by McDermott John D, worth $111,250. Zenty III Thomas F had bought 5,000 shares worth $22,200 on Monday, May 22. $86,400 worth of Endologix, Inc. (NASDAQ:ELGX) was bought by NEELS GUIDO J on Friday, May 19. The insider Lemaitre Dan bought 22,522 shares worth $99,772.

Investors wait Endologix, Inc. (NASDAQ:ELGX) to report on November, 7. its quarterly earnings Wall Street analysts expect $-0.17 EPS, down $0.06 or 54.55 % from last year’s $-0.11 same quarter earnings. Endologix, Inc.’s Wall Street analysts see 70.00 % negative EPS growth, taking into account the $-0.10 EPS reproted in the previous quarter, The stock decreased 1.16% or $0.06 on October 13, reaching $5.1. About 410,612 shares traded. Endologix, Inc. (NASDAQ:ELGX) has declined 63.00% since October 15, 2016 and is downtrending. It has underperformed by 79.70% the S&P500.

Endologix, Inc. (NASDAQ:ELGX) Ratings Coverage

Among 10 analysts covering Endologix Inc. (NASDAQ:ELGX), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Endologix Inc. has $20 highest and $5.0 lowest target. $7.75’s average target is 51.96% above currents $5.1 stock price. Endologix Inc. had 40 analyst reports since August 4, 2015 according to SRatingsIntel. Oppenheimer maintained Endologix, Inc. (NASDAQ:ELGX) rating on Thursday, August 3. Oppenheimer has “Hold” rating and $500 target. BMO Capital Markets maintained it with “Hold” rating and $500 target in Wednesday, August 2 report. RBC Capital Markets maintained the shares of ELGX in report on Tuesday, May 10 with “Outperform” rating. BTIG Research upgraded the stock to “Buy” rating in Monday, September 28 report. The firm has “Hold” rating by Stifel Nicolaus given on Friday, October 6. On Monday, April 4 the stock rating was reinitiated by JP Morgan with “Overweight”. RBC Capital Markets maintained Endologix, Inc. (NASDAQ:ELGX) on Monday, July 31 with “Hold” rating. RBC Capital Markets maintained it with “Hold” rating and $5.0 target in Monday, October 2 report. The stock has “Market Perform” rating by BMO Capital Markets on Tuesday, October 27. The stock of Endologix, Inc. (NASDAQ:ELGX) has “Buy” rating given on Monday, June 13 by Canaccord Genuity.

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The company has market cap of $425.52 million. The Company’s products are intended for the treatment of abdominal aortic aneurysms . It currently has negative earnings. The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

More news for Endologix, Inc. (NASDAQ:ELGX) were recently published by: Businesswire.com, which released: “Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7 …” on October 10, 2017. Streetinsider.com‘s article titled: “Form 8-K ENDOLOGIX INC /DE/ For: Oct 06” and published on October 06, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com